Structural basis for ligand recognition of the neuropeptide Y Y2 receptor

被引:25
作者
Tang, Tingting [1 ,2 ,3 ]
Hartig, Christin [4 ]
Chen, Qiuru [1 ,3 ,5 ]
Zhao, Wenli [1 ,2 ,3 ]
Kaiser, Anette [4 ]
Zhang, Xuefeng [1 ,2 ,3 ]
Zhang, Hui [1 ,2 ,3 ]
Qu, Honge [1 ,3 ,5 ]
Yi, Cuiying [1 ]
Ma, Limin [2 ]
Han, Shuo [2 ]
Zhao, Qiang [2 ,3 ,6 ,7 ]
Beck-Sickinger, Annette G. [4 ]
Wu, Beili [1 ,3 ,5 ,6 ,7 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China
[2] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China
[3] Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China
[4] Univ Leipzig, Inst Biochem, Fac Life Sci, Bruderstr 34, D-04103 Leipzig, Germany
[5] ShanghaiTech Univ, Sch Life Sci & Technol, 393 Hua Xia Zhong Rd, Shanghai 201210, Peoples R China
[6] Chinese Acad Sci, CAS Ctr Excellence Biomacromol, Beijing 100101, Peoples R China
[7] UCAS, Hangzhou Inst Adv Study, Sch Pharmaceut Sci & Technol, Hangzhou 310024, Peoples R China
基金
美国国家科学基金会; 国家重点研发计划;
关键词
PEPTIDE YY; NPY SYSTEM; BINDING; ANTAGONIST; RESIDUES; BONE;
D O I
10.1038/s41467-021-21030-9
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The human neuropeptide Y (NPY) Y-2 receptor (Y2R) plays essential roles in food intake, bone formation and mood regulation, and has been considered an important drug target for obesity and anxiety. However, development of drugs targeting Y2R remains challenging with no success in clinical application yet. Here, we report the crystal structure of Y2R bound to a selective antagonist JNJ-31020028 at 2.8 angstrom resolution. The structure reveals molecular details of the ligand-binding mode of Y2R. Combined with mutagenesis studies, the Y2R structure provides insights into key factors that define antagonistic activity of diverse antagonists. Comparison with the previously determined antagonist-bound Y1R structures identified receptor-ligand interactions that play different roles in modulating receptor activation and mediating ligand selectivity. These findings deepen our understanding about molecular mechanisms of ligand recognition and subtype specificity of NPY receptors, and would enable structure-based drug design. The human neuropeptide Y receptor Y-2 (Y2R) is a drug target for the treatment of obesity and anxiety. Crystal structure of Y2R bound to a selective antagonist and accompanying mutagenesis provide insights into ligand recognition and subtype specificity of NPY receptors.
引用
收藏
页数:9
相关论文
共 48 条
[31]   Neuropeptide YY2 receptor in health and disease [J].
Parker, S. L. ;
Balasubramaniam, A. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 (03) :420-431
[32]  
Pedragosa-Badia Xavier, 2013, Front Endocrinol (Lausanne), V4, P5, DOI 10.3389/fendo.2013.00005
[33]   Protein crystal quality oriented disulfide bond engineering [J].
Pu, Mengchen ;
Xu, Zhijie ;
Peng, Yao ;
Hou, Yaguang ;
Liu, Dongsheng ;
Wang, Yang ;
Liu, Haiguang ;
Song, Gaojie ;
Liu, Zhi-Jie .
PROTEIN & CELL, 2018, 9 (07) :659-663
[34]   Neuropeptide Y is an angiogenic factor in cardiovascular regeneration [J].
Saraf, Rabya ;
Mahmood, Feroze ;
Amir, Rabia ;
Matyal, Robina .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2016, 776 :64-70
[35]   Modulation of neuropeptide Y receptors for the treatment of obesity [J].
Sato, Nagaaki ;
Ogino, Yoshio ;
Mashiko, Satoshi ;
Ando, Makoto .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (10) :1401-1415
[36]   Structure-Energy Relationships of Halogen Bonds in Proteins [J].
Scholfield, Matthew R. ;
Ford, Melissa Coates ;
Carlsson, Anna-Carin C. ;
Butta, Hawera ;
Mehl, Ryan A. ;
Ho, P. Shing .
BIOCHEMISTRY, 2017, 56 (22) :2794-2802
[37]   Central and peripheral mechanisms of the NPY system in the regulation of bone and adipose tissue [J].
Shi, Yan-Chuan ;
Baldock, Paul A. .
BONE, 2012, 50 (02) :430-436
[38]   In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor [J].
Shoblock, James R. ;
Welty, Natalie ;
Nepomuceno, Diane ;
Lord, Brian ;
Aluisio, Leah ;
Fraser, Ian ;
Motley, S. Timothy ;
Sutton, Steve W. ;
Morton, Kirsten ;
Galici, Ruggero ;
Atack, John R. ;
Dvorak, Lisa ;
Swanson, Devin M. ;
Carruthers, Nicholas I. ;
Dvorak, Curt ;
Lovenberg, Timothy W. ;
Bonaventure, Pascal .
PSYCHOPHARMACOLOGY, 2010, 208 (02) :265-277
[39]   Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER [J].
Smart, Oliver S. ;
Womack, Thomas O. ;
Flensburg, Claus ;
Keller, Peter ;
Paciorek, Wlodek ;
Sharff, Andrew ;
Vonrhein, Clemens ;
Bricogne, Gerard .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2012, 68 :368-380
[40]   The discovery and synthesis of JNJ 31020028, a small molecule antagonist of the Neuropeptide Y Y2 receptor [J].
Swanson, Devin M. ;
Wong, Victoria D. ;
Jablonowski, Jill A. ;
Shah, Chandra ;
Rudolph, Dale A. ;
Dvorak, Curt A. ;
Seierstad, Mark ;
Dvorak, Lisa K. ;
Morton, Kirsten ;
Nepomuceno, Diane ;
Atack, John R. ;
Bonaventure, Pascal ;
Lovenberg, Timothy W. ;
Carruthers, Nicholas I. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (18) :5552-5556